A New Blog Series: The Ins And Outs Of Clinical Trials

image005In our new 10 part blog series on clinical trials, Sharmela Thevarajaha, Associate, Intellectual Property and Life Sciences, brings her wealth of private practice and in-house experience with clients such as Sanofi and Takeda, to take a look at some key clauses within a sponsor-initiated clinical trial agreement.

In the series she highlights the crucial legal, ethical and business issues to consider when negotiating these key provisions including payments, intellectual property, insurance and publication rights.

______

Clinical research collaboration plays a significant role in developing medicines, advancing medical knowledge and enhancing patient care.  

Without clinical trials, pharmaceutical companies (the sponsors), wouldn’t be able to get drugs to market in order to save lives and continue to build a real world body of knowledge around medicines.

Clinical trial agreements are laden with detail to capture the commercial, ethical and financial obligations of the sponsor, institution and the principal investigator (being doctor/ lead researcher conducting the clinical trial). Considering the detail involved experienced and educated negotiation is essential for all parties to reach a consensus and save time, money and resources.

The list of provisions is intended as a high-level guide only and is not intended to be comprehensive and certainly does not capture every provision that can be found in a clinical trial agreement.

First up – Obligations.

Obligations of the sponsor – The sponsor’s main role is:

  • Initiating, managing and financing the clinical trial.
  • Creating the protocol setting out the goals of the clinical trial.
  • Arranging training for the principal investigator (PI) and others involved in the clinical trial.
  • Being responsible for data protection matters; and monitoring and safety reporting to regulatory authorities.

The sponsor must be satisfied the protocol, research team and research environment have passed scientific quality assurance and the trial has received approval from the relevant regulatory body and ethic committees before it begins.

Obligations of the clinical research organisation (CRO) – The management of a clinical trial is an incredibly time-consuming and resource intensive activity that many sponsors outsource to a CRO but the ultimate responsibility for the quality and integrity of the trial data remains with the sponsor.  The International Conference on Harmonisation Guidelines for Good Clinical Practice recommends any trial-related duty and function which is transferred to and undertaken by the CRO is specified in writing. Non transferred duties remain with the sponsor.

Obligations of the institution – The institution must recognise both the legal and ethical responsibilities it owes to the subjects and the sponsor. The institution is responsible for:

  • The clinical trial site and facilities.
  • Complying with the protocol.
  • Ensuring the PI and any other staff are executing the trial in accordance with applicable laws, industry best practices, ethics committee accreditation, standard operating procedures and monitoring protocols.
  • Verifying academic and professional qualifications, experiences and the training of the PI and the research staff.

Obligations of the PI – The PI’s main role is:

  • Supervising the clinical trial and ensures the welfare of the clinical trial subjects.
  • Providing medical assistance to subjects.
  • Obtaining consent from the subjects, ethics committee approvals, and any other approvals required to perform their obligations.

When negotiating the clinical trial agreement, the parties should also consider what rights the sponsor has in the event the PI can no longer act as the PI, such as the institution seeking prior written approval for a substitute PI from the sponsor.  

Also, PIs may be involved in competing clinical trials simultaneously, which could lead to a conflict of interest. If this is a concern, the sponsor should have a requirement in the contract preventing this.

Last and certainly not least, is the transfer of obligations in clinical trials.

The transfer of rights and obligations are most commonly dealt with in the assignment provision of the agreement. As the sponsor is ultimately responsible for the trial, no party (CRO, PI and institution) should be able to transfer any of their obligations without the sponsor’s express consent.

Also, as a sponsor, if one of the party is not performing, it should have the ability to remove them and either step in or arrange for a third party to step in. The PI and institution in particular may not find this stance acceptable, however, unless it’s commercially unviable to give up on this point, it’s best to state that the PI and institution cannot assign or transfer the agreement without the sponsor’s permission.  

A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. more information

INFORMATION ABOUT OUR USE OF COOKIES Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience and also allows us to improve our website. By continuing to browse the website, you are agreeing to our use of cookies. A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. We use the following cookies: • Strictly necessary cookies. These are cookies that are required for the operation of our website. They include, for example, cookies that enable you to return to a previous page. • Analytical/performance cookies. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily. The analytical/performance cookies are provided on our behalf by Google Inc. to aid with reporting of user behaviour, market research and improving website functionality. This user behaviour is analysed in order to improve this website. To see how this applies to Google Analytics, visit http://www.google.co.uk/intl/en/analytics/privacyoverview.html. You can stop tracking by Google Analytics by visiting https://tools.google.com/dlpage/gaoptout?hl=en-GB. COOKIE DURATION The strictly necessary session cookies are a temporary cookie which remains in the cookie file of your browser until you close the browser. The other cookies will remain in the cookie file of your browser after the closing of the browser, and will become active again when you reopen this website. The different cookies have different expiration dates. Following expiry of a cookie, a new version of that cookie will be downloaded when you next visit this website, unless you have withdrawn your consent in the meantime. You can block cookies by activating the setting on your browser that allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or parts of our website. Contact If you have any queries regarding this cookie policy please contact us at info@jagshawbaker.com.

Close